Logo image of ECAT

BLACKROCK ESG CAP ALL TRM TR (ECAT) Stock Price, Quote, News and Overview

NYSE:ECAT - New York Stock Exchange, Inc. - US09262F1003 - Currency: USD

16.25  -0.06 (-0.37%)

After market: 16.22 -0.03 (-0.18%)

Fundamental Rating

3

ECAT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. ECAT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ECAT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ECAT was profitable.
ECAT had a positive operating cash flow in the past year.
ECAT Yearly Net Income VS EBIT VS OCF VS FCFECAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -500M -1B -1.5B -2B

1.2 Ratios

Industry RankSector Rank
ROA 12.18%
ROE 13.1%
ROIC 1.49%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ECAT Yearly ROA, ROE, ROICECAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 10 -10

1.3 Margins

ECAT's Profit Margin has declined in the last couple of years.
Industry RankSector Rank
OM 56.45%
PM (TTM) 388.71%
GM 61.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.47%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ECAT Yearly Profit, Operating, Gross MarginsECAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 1K 2K

More info and screens

3

2. Health

2.1 Basic Checks

ECAT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ECAT Yearly Shares OutstandingECAT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M 80M 100M
ECAT Yearly Total Debt VS Total AssetsECAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 6.98 indicates that ECAT is not in any danger for bankruptcy at the moment.
The Debt to FCF ratio of ECAT is 0.02, which is an excellent value as it means it would take ECAT, only 0.02 years of fcf income to pay off all of its debts.
A Debt/Equity ratio of 0.00 indicates that ECAT is not too dependend on debt financing.
Although ECAT does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Altman-Z 6.98
ROIC/WACCN/A
WACCN/A
ECAT Yearly LT Debt VS Equity VS FCFECAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 1B -1B 2B -2B

2.3 Liquidity

ECAT has a Current Ratio of 0.10. This is a bad value and indicates that ECAT is not financially healthy enough and could expect problems in meeting its short term obligations.
ECAT has a Quick Ratio of 0.10. This is a bad value and indicates that ECAT is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
ECAT Yearly Current Assets VS Current LiabilitesECAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ECAT have decreased strongly by -14.89% in the last year.
Measured over the past years, ECAT shows a very strong growth in Earnings Per Share. The EPS has been growing by 45.23% on average per year.
The Revenue has been growing slightly by 4.50% in the past year.
The Revenue has been growing by 175.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-14.89%
EPS 3Y45.23%
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)4.5%
Revenue growth 3Y175.73%
Revenue growth 5YN/A
Sales Q2Q%-0.47%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ECAT Yearly Revenue VS EstimatesECAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 20M 40M 60M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 6.77 indicates a rather cheap valuation of ECAT.
When comparing the Price/Earnings ratio of ECAT to the average of the S&P500 Index (26.82), we can say ECAT is valued rather cheaply.
Industry RankSector Rank
PE 6.77
Fwd PE N/A
ECAT Price Earnings VS Forward Price EarningsECAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 4.78
EV/EBITDA N/A
ECAT Per share dataECAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 20.37%, ECAT is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.35, ECAT pays a better dividend.
Industry RankSector Rank
Dividend Yield 20.37%

5.2 History

ECAT has been paying a dividend for over 5 years, so it has already some track record.
ECAT has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years3
Div Non Decr Years3
ECAT Yearly Dividends per shareECAT Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

119.50% of the earnings are spent on dividend by ECAT. This is not a sustainable payout ratio.
DP119.5%
EPS Next 2YN/A
EPS Next 3YN/A
ECAT Yearly Income VS Free CF VS DividendECAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 0 -500M -1B -1.5B -2B
ECAT Dividend Payout.ECAT Dividend Payout, showing the Payout Ratio.ECAT Dividend Payout.PayoutRetained Earnings

More info and screens

BLACKROCK ESG CAP ALL TRM TR

NYSE:ECAT (8/1/2025, 8:04:00 PM)

After market: 16.22 -0.03 (-0.18%)

16.25

-0.06 (-0.37%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)09-01 2025-09-01
Inst Owners45.28%
Inst Owner Change0.08%
Ins Owners0.11%
Ins Owner Change86.97%
Market Cap1.61B
Analysts0
Price TargetN/A
Short Float %0.19%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield 20.37%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP119.5%
Div Incr Years3
Div Non Decr Years3
Ex-Date07-15 2025-07-15 (0.29365)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 6.77
Fwd PE N/A
P/S 26.04
P/FCF 4.78
P/OCF 4.78
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)2.4
EY14.77%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)3.4
FCFY20.94%
OCF(TTM)3.4
OCFY20.94%
SpS0.62
BVpS18.51
TBVpS18.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.18%
ROE 13.1%
ROCE 1.9%
ROIC 1.49%
ROICexc 1.49%
ROICexgc 1.52%
OM 56.45%
PM (TTM) 388.71%
GM 61.29%
FCFM 545.16%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.47%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 140.25%
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z 6.98
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.89%
EPS 3Y45.23%
EPS 5YN/A
EPS Q2Q%-25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.5%
Revenue growth 3Y175.73%
Revenue growth 5YN/A
Sales Q2Q%-0.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y103.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y103.61%
OCF growth 3YN/A
OCF growth 5YN/A